Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26622106 | 0.89 | TAAR1 (0.54) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL27920637 | 0.87 | HDAC3 (0.40) | SLC6A4SLC6A2SLC6A3NTRK1ALDH1A1 | |
| SCHEMBL2116744 | 0.85 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3NTRK1MEN1 | |
| SCHEMBL11825653 | 0.81 | IDO1 (0.56) | HTR2A | |
| SCHEMBL30861233 | 0.81 | IDO1 (0.56) | HTR2A | |
| SCHEMBL5479089 | 0.81 | ACHE (0.50) | MEN1ALDH1A1POLBHPGDKMT2A | |
| SCHEMBL6911481 | 0.80 | CYP1A2 (0.39) | SLC6A4ALDH1A1HPGDHTR2A | |
| SCHEMBL4171690 | 0.80 | KDM4E (0.50) | MEN1ALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL4522555 | 0.80 | KDM4E (0.56) | ALDH1A1HTR2AKDM4E | |
| SCHEMBL27758118 | 0.80 | SLC6A4 (0.49) | SLC6A4SLC6A3MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351577-B2 | Inhibiting cyclic AMP-responsive element-binding protein (CREB) | FORMA THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250188079-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | FORMA THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| WO-2025089147-A1 | HERBICIDAL COMPOSITION | 株式会社エス・ディー・エス バイオテック | 2025-05-01 | — | — | WO | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-111971287-B | Macrocyclic compounds as TRK kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | FOCHON BIOSCIENCES, LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20220213089-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | FORMA THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220213089-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | FORMA THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| WO-2022020247-A1 | SMALL MOLECULE CORRECTORS OF MAMMALIAN SLC6A8 FUNCTION | JNANA THERAPEUTICS, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3937940-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | Forma Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7087644-B1 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1216225-B1 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | SLC6A4 1575/4885SLC6A2 2554/4885SLC6A3 2930/4885 |
| US-20250188079-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | CREBBP, CREB1, EP300 | SLC6A4 4347/4885SLC6A2 4536/4885SLC6A3 4037/4885 |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | DDC, AADAT, PTGIS | SLC6A4 1575/4885SLC6A2 2554/4885SLC6A3 2930/4885 |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | PLK2, ERBB3, DMPK | SLC6A4 4223/4885SLC6A2 4577/4885SLC6A3 4436/4885 |
| US-12351577-B2 | Inhibiting cyclic AMP-responsive element-binding protein (CREB) | CREBBP, CREB1, EP300 | SLC6A4 4347/4885SLC6A2 4536/4885SLC6A3 4037/4885 |
| US-20220213089-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | CREBBP, CREB1, EP300 | SLC6A4 4347/4885SLC6A2 4536/4885SLC6A3 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.